Skip to main content
Newcastle Clinical Trials Unit
Search for something
Search...

Oral

ENHANCE-D - Recruiting

The ENHANCE-D Study – ENHANCing smoking cEssation interventions in Dentistry

  • Study stage: Recruiting
  • Sponsor: The Newcastle upon Tyne Hospitals NHS Foundation Trust
  • Funder: NIHR HTA
  • Therapeutic area: Oral
  • Type of study: CTIMP

Aim:  To compare smoking abstinence at 6 months of Nicotine Replacement Therapy (NRT)  and  E-cigarette (EC) to usual care and to each other.

Primary Outcome:  Biochemically verified smoking abstinence at 6 months

  • Clinical Phase: IIII
  • Population: Adults
  • Design: RCT
  • Setting: Primary care (NHS Dental Care)
  • Planned Sample Size: 1215

Website:  https://research.ncl.ac.uk/enhance-d/

Fiction - Closed

Filling Children’s Teeth: Indicated or Not? 

  • Study stage: Closed
  • Sponsor:  University of Dundee
  • Funder:  NIHR HTA
  • Therapeutic area: Oral
  • Type of study:  Clinical Intervention

Aim:

Compare these three treatment strategies, when applied over a period of up to three years to 3-7 year old children with caries in primary teeth, with respect to the clinical outcomes of incidence and number of episodes of dental pain and dental sepsis.

Primary Outcome:

Either pain or sepsis related to dental caries.

  • Population: Paediatrics
  • Design: RCT
  • Setting: Primary care (NHS Dental Care)
  • Planned Sample Size: 1113

MiTiGate - In Set-up

The MiTiGaste Study - Are Botox Lidocaine more effective than treatment as usual in myalgia Temporomandibular Disorder (M-TMD)?

  • Study stage: In Set-up
  • Sponsor: The Newcastle upon Tyne Hospitals NHS Foundation Trust
  • Funder: NIHR HTA
  • Therapeutic area: Oral & Dental
  • Type of study: CTIMP

Aim:

To provide evidence about the most effective treatment to reduce pain and improve quality of life for people livingwith M-TMD, and which treatment is cost effecive.

Primary Outcome:

To determine whether Botox or lidocine are superior to treatment as usal (amitriptyline/gabapentin) in reducing pain intensity and improving quality of life and to assess cost-effectiveness of the most effective treatment in comparison to the other treatment at 36 weeks.

  • Clinical Phase: IIII
  • Population: People with chronic M-TMD
  • Design: RCT
  • Setting: Secondary Care
  • Planned Sample Size: 663
Back to our trials